Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EASE-2: Empagliflozin as Adjunctive to Insulin in Type 1 Diabetes
NCT01969747Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2013
- Primary completion
- Apr 2014
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of empagliflozin in type 1 diabetes mellitus (T1D), sponsored by Boehringer Ingelheim. Started Nov 2013; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT01969747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01969747.